ClinicalTrials.gg
RecruitingNCT07064122Updated Mar 2, 2026

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

A Phase 1 interventional study of AZD2962 in Haematologic Neoplasms, sponsored by AstraZeneca. Recruiting at 21 sites in 7 countries. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years to 110 Years
Sex
All
01

Study summary

The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.

Read the detailed description

This is a modular study. In Module 1, the study will begin with a dose escalation of AZD2962 monotherapy in participants with myelodysplastic syndromes (MDS) and dysplastic chronic myelomonocytic leukemia (CMML).

Module 1 of the study will comprise of:

  1. A Screening Period of maximum 21 days.
  2. Treatment period with 28-day cycles where each patient will receive an oral dose of AZD2962 once daily, starting on Day 1, and will continue treatment until disease progression, unacceptable toxicity, or withdrawal.
  3. Safety Follow-up period after 30 days after last dose.
02

Conditions studied

  • Haematologic Neoplasms

Keywords

  • Interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor
  • Modular study
  • Pharmacokinetics
  • Dose escalation
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with MDS or participants with relapsed/refractory dysplastic CMML, with peripheral blasts or bone marrow blasts \< 20%, and who received one or more as per standard of care (or who exhausted locally available treatments including treatments for actionable mutations). Diagnosis must be confirmed as per the WHO 2016 classification of myeloid neoplasms.
  2. (ECOG) performance status of ≤2.
  3. Participants must have symptomatic disease that requires therapy and allows for objective efficacy assessments.
  4. Willing to provide baseline bone marrow aspirate (or if dry-tap).
  5. use by participants or participant partners should be consistent with local regulations and also comply with Clinical Study Protocol requirements.
  6. All women of must have a negative serum pregnancy test result at Screening.

Key Exclusion Criteria:

  1. Prior treatment with IRAK inhibitors or inhibitors of the inflammasome pathway.
  2. Received any antineoplastic therapy (except hydroxyurea) within 15 days prior to first dose.
  3. Received any strong or moderate Cytochrome P450 3A () inhibitors within 15 days prior to first dose.
  4. Received major surgery within 28 days prior to first dose, or still recovering from surgery.
  5. Received drugs that are known to prolong interval (QTc) and with known risk of Torsades de Pointes, within 15 days prior to first dose.
  6. Received medications (including prophylaxis) within 28 days prior to first dose, or within 15 days in the case of systemic (doses exceeding 10 mg/day of prednisone or equivalent).
  7. Received within 28 days prior to first dose.
  8. Active major bleeding event.
  9. Any evidence of systemic disease, significant clinical disorder, or laboratory finding that make undesirable the participation in the study.

15. Mean resting corrected QT interval using Fridericia's formula (QTcF) > 450 ms obtained from triplicate (ECGs) and averaged, recorded within 5 minutes. In the presence of bundle branch block, QTcF > 470 ms is applicable.

16. History of intracranial bleeding within 6 months prior to first dose. 17. Active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of oral therapy.

18. History of a prior non-haematologic neoplasm (with some exceptions). 19. Unresolved Grade > 2 toxicities from prior anticancer therapies (with some exceptions).

20. Concurrent enrolment in another clinical study (with some exceptions). 21. Known to study intervention or its .

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Module 1- AZD2962 (Monotherapy)

    Participants with MDS and dysplastic CMML will receive AZD2962 as monotherapy in a dose escalation pattern.

    Drug: AZD2962

Interventions

  • DrugAZD2962

    AZD2962 will be administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicity (DLT)

    A DLT is defined as an adverse event or abnormal laboratory value occurring during the DLT-evaluation period (first 28 days of treatment). This will be evaluated to assess the safety and tolerability and also to identify optimal biological dose (OBD) of AZD2962.

    Time frame: From Cycle 1 Day 1 up to end of Cycle 1 (28 Days)

  2. Number of participants with Adverse events (AEs) and serious AEs

    To assess the safety and tolerability of AZD2962 and also to identify OBD of AZD2962.

    Time frame: Cycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)

  3. Duration of exposure

    To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.

    Time frame: Cycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)

  4. Relative dose intensity

    To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.

    Time frame: Cycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)

Secondary outcomes

  1. Percentage of participants with Objective response (OR)

    For participants with MDS or CMML, OR is defined as the achievement of Best Overall Response (BOR) assessed by relevant criteria for the selected haematologic neoplasm. The OR will be assessed to estimate the efficacy of AZD2962.

    Time frame: First dose up to progression of disease (PD) or last evaluable assessment in the absence of progression, whichever comes first (Approximately 3 Years)

  2. Duration of response (DoR)

    The DoR is defined as the time from the date of first documented OR until date of first documented PD or death (by any cause in the absence of PD), regardless of discontinuation of study interventions or receiving another anticancer therapy. The DoR will be assessed to estimate the efficacy of AZD2962.

    Time frame: First documented response, up to the date of the first documented PD or study end, which ever comes first (Approximately 3 Years)

  3. Time to Response (TTR)

    The TTR is defined as the time between start of treatment and the date of documented confirmed objective response for the selected haematologic neoplasm. The TTR will be assessed to estimate the efficacy of AZD2962.

    Time frame: First dose up to PD or last evaluable assessment, whichever comes first (Approximately 3 Years)

  4. Overall Survival (OS)

    The OS is defined as the time from the date of first dose until death due to any cause regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy. The OS will be assessed to estimate the efficacy of AZD2962.

    Time frame: First dose up to death due to any cause (Approximately 3 Years)

  5. Time to Progression to Acute myeloid leukaemia (AML)

    Time to progression to AML as per World Health Organization (WHO) 2016 is defined from the time of first dose until first diagnosis of AML, regardless of discontinuation of treatment or receiving another anti-cancer therapy. This will be assessed to estimate the efficacy of AZD2962.

    Time frame: First dose up to first diagnosis of AML (Approximately 3 Years)

  6. Plasma concentration of AZD2962

    To characterise the plasma concentration of AZD2962 as monotherapy.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) up to end of the treatment (EoT) (Approximately 3 Years)

  7. Area under the concentration time curve (AUC).

    To characterise the pharmacokinetics (PK) AUC of AZD2962 as monotherapy.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) up to EoT (Approximately 3 Years)

  8. Maximum plasma drug concentration (Cmax)

    To characterise the PK (Cmax) of AZD2962 as monotherapy.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) up to EoT (Approximately 3 Years)

  9. Time to reach maximum concentration (tmax)

    To characterise the PK (tmax) of AZD2962 as monotherapy.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) up to EoT (Approximately 3 Years)

07

Study locations

15 of 21 sites recruiting
  • Research Site
    Miami, Florida 33136, United States
    Not yet recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Heidelberg, 3084, Australia
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Shinagawa-ku, 141-0022, Japan
    Recruiting
  • Research Site
    Yoshida-gun, 910-1193, Japan
    Recruiting
  • Research Site
    Seoul, 05505, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Seoul, 3722, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Barcelona, 08035, Spain
    Recruiting
  • Research Site
    Madrid, 28027, Spain
    Recruiting
  • Research Site
    Madrid, 28033, Spain
    Recruiting
  • Research Site
    Pamplona, 31008, Spain
    Recruiting
  • Research Site
    Salamanca, 37007, Spain
    Recruiting
  • Research Site
    Valencia, 46026, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Kaohsiung City, 83301, Taiwan
    Not yet recruiting
  • Research Site
    Tainan, 70403, Taiwan
    Not yet recruiting
  • Research Site
    Taipei, 100, Taiwan
    Recruiting
  • Research Site
    London, SE5 9RS, United Kingdom
    Recruiting
  • Research Site
    London, W1T 7HA, United Kingdom
    Recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Oct 20, 2028
CompletionEst.
Oct 20, 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07064122
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Nov 3, 2025
Primary completion
Oct 20, 2028 (estimated)
Completion
Oct 20, 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion